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ttp://dx.doi.org/10.1016/j.jmoldx.2012.06.008Control of biospecimen quality that is linked to processing is one of the goals of biospecimen science.
Consensus is lacking, however, regarding optimal sample quality-control (QC) tools (ie, markers and
assays). The aim of this review was to identify QC tools, both for ﬂuid and solid-tissue samples, based on
a comprehensive and critical literature review. The most readily applicable tools are those with a known
threshold for the preanalytical variation and a known reference range for the QC analyte. Only a few
meaningful markers were identiﬁed that meet these criteria, such as CD40L for assessing serum exposure
at high temperatures and VEGF for assessing serum freeze-thawing. To fully assess biospecimen quality,
multiple QC markers are needed. Here we present the most promising biospecimen QC tools that were
identiﬁed. (J Mol Diagn 2013, 15: 3e16; http://dx.doi.org/10.1016/j.jmoldx.2012.06.008)Disclosure: F.B. was previously employed by the Picardie Biobank,
which holds a French patent on the use of sCD40L as a quality-control
marker in serum, based on her previous work.
The 2011 Biospecimen Science Working Group consisted of Fotini (Fay)
Betsou (Chair), Garry Ashton, Michael Barnes, Erica E. Benson, Rodrigo
Chuaqui, Judith Clements, Domenico Coppola, Yvonee De Souza, Anne-
mieke De Wilde, James F. Eliason, Barbara Glazaer, Katrina Goddard,
Fiorella Guadagni, Elaine Gunter, Keith Harding, Jae-Pil Jeon, Olga Kofa-
nova, Conny Mathay, Rolf Muller, Francesca Poloni, Katheryn E. Shea,
Amy P.N. Skubitz, Mark E. Sobel, Stella Somiari, and Gunnel Tybring.One of the main goals in biospecimen science is to identify
and control the potential bias due to biospecimen processing
or quality on the molecular analyses. Several recent studies
have recognized the inﬂuence of preanalytical variables (eg,
warm or cold ischemia times, or delays in processing1) on
the integrity of biomolecules.
For example, gene proﬁling of peripheral blood cells of
patients has the potential to advance our understanding of
a variety of human diseases. Appropriate biomarkers can
improve diagnosis and clinical management of patients.
However, to optimize cell gene expression data for trans-
lational studies, it is essential to control the preanalyticalstigative Pathology
.variables that produce changes in gene expression, variables
that are unrelated to the disease condition being studied.
Betsou et alControlling preanalytical variables is a particularly chal-
lenging and complex issue, because the inﬂuence of the
quality of a sample on the molecular data obtained from its
analysis depends not only on the class of biomolecule
analyzed (DNA, RNA, protein, metabolite) but also on the
type of analytical method (multiplex versus singleplex,
qualitative versus quantitative) and the speciﬁcity, sensitivity,
and robustness of the method against speciﬁc preanalytical
variations. Biobanking method validation requires both
knowledge of the preanalytical variables that need to be
controlled and identiﬁcation of those factors that do not affect
the quality of the biospecimen for a given type of research.
To address this major goal of controlling for preanalytical
variables, two main approaches are used in biospecimen
science-driven biobanking. The ﬁrst is to optimize the quality
of biospecimens and thus to directly minimize and/or control
the preanalytical bias. Unfortunately, in most clinical settings
there is only limited ability to control preanalytical variables
inﬂuencing biomolecule integrity, such as surgery or warm
ischemia time. In a clinical context, therefore, a second
approach must be to retrospectively apply appropriate tests to
accurately assess the global biomolecular integrity status of
each biospecimen. This process becomes critical for high-
throughput, quantitative downstream assays implemented as
clinical molecular diagnostics.
Once the most critical points in a biospecimen processing
method have been identiﬁed, speciﬁc tests or markers to
assess the quality of the biospecimen are needed. These may
be called surrogate quality biomarkers or surrogate quality
indicators. At present, there are few appropriate quality-
control tools that either are predictive of downstream
method feasibility [eg, DNA methylation analysis on DNA
extracted from formalin-ﬁxed, parafﬁn-embedded (FFPE)
tissue] and reliability (eg, feasibility of methylation analysis
does not guarantee its accuracy) or are diagnostic of
upstream biospecimen processing steps (eg, tissue ﬁxation
time) (Figure 1). Quality control (QC) in the form of diag-
nostic tests of upstream biospecimen processing steps is
called biospecimen molecular diagnostics or preanalyticalBiospecimen Sample Result
Collection
Processing 
Storage
QC diagnostic of 
collection / processing / 
storage steps
QC predictive of 
analysis feasibility / validity
Analysis
Figure 1 Quality control assays, applied on biological samples, can be
either diagnostic of upstream collection, processing, and/or storage
conditions or predictive of the feasibility and/or validity of downstream
analysis performed with the samples.
4characterization. Ultimately, preanalytical characterization
should allow researchers to assess the reliability of a speciﬁc
type of downstream analysis.
Several steps are needed to solve these issues. First, the
scientiﬁc community must agree on the elements from the life
cycle of the biospecimen that should be documented in
scientiﬁc publications, as has been proposed in the Bio-
specimen Reporting for Improved Study Quality (BRISQ)
recommendations.2 Second, these elements must be codiﬁed,
so that their recording and communication is standardized.
For example, the ISBER Biospecimen Science Working
Group has developed a standard preanalytical code to identify
the main preanalytical variables for both ﬂuid and solid-tissue
biospecimens and their simple derivatives.3 Finally, it is
critical to perform biospecimen research to identify the key
biomarkers that will predict sample integrity and quality.4
Different QC assays are used to characterize viable and
nonviable biospecimens. In the ﬁrst case, viability and
functionality (eg, pluripotency, response to antigens,
motility) are assessed through microscopy, ﬂow cytom-
etry, or immunoenzymatic assays. In the case of nonviable
specimens, molecular integrity (eg, protein phosphoryla-
tion status, epitope conformation, rRNA degradation,
DNA cross-linking degree) is generally assessed through
immunoenzymatic, electrophoretic, and molecular bio-
logic assays.5
It is critical to deﬁne and standardize the assays used to
assess the molecular integrity of biospecimens procured in
a clinical setting, because there is no consensus in the
literature on which biospecimen quality markers or tools
provide the best biospecimen molecular diagnostic perfor-
mance and information. For example, standard approaches
to assessing RNA integrity, such as ribosomal RNA
measurements and RNA integrity number (RIN), are neither
sensitive nor speciﬁc enough to assess potential bias in
downstream gene expression analysis.6
The goal of this literature review was to identify tools
(markers and assays) that can be used to assess preanalytical
variations for both ﬂuid and solid tissue-derived samples.
Deﬁning the most appropriate assays used to assess bio-
specimen quality, as well as the methods for standardization
between laboratories through external quality assessment,
remains an open question. Furthermore, it is imperative to
deﬁne the analytical data that can be reliably obtained
within different sample quality categories, and to develop
methods to overcome pitfalls linked to issues of sample
quality. The scope of the present review is limited to
upstream QC of the biospecimen. We did not address
downstream QC of the end-use results, such as gene
expression microarray parameters. The scope of the review
encompasses both clinical biology and research laboratory
settings: on the one hand, information that has previously
been published in a clinical setting can be applied to
research; on the other hand, high-throughput assays initially
performed only in research settings may later be imple-
mented in clinical practice.jmd.amjpathol.org - The Journal of Molecular Diagnostics
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Biospecimen Science-Speciﬁc Literature Compilation
Members of the ISBER Biospecimen Science Working
Group searched PubMed (http://www.ncbi.nlm.nih.gov/
pubmed) using keywords such as analyte, stability, pre-
analytical, and specimen, and then compiled all identiﬁed
publications that dealt with biomolecules and biospecimen
analytical behavior. Relevant literature from other sources
on the same subjects was also included, including pro-
ceedings from meetings, as well as guidelines and recom-
mendations. Additional potential sources of information
were identiﬁed by members of the working group; these
included selected publications on basic and clinical research
and DNA, RNA, and protein analysis from studies that used
samples from tissue resources (the Cooperative Human
Tissue Network, Cooperative Group Banks) and other
programs (Innovative Molecular Analysis Technologies) of
the U.S. National Cancer Institute.Biospecimen Science-Speciﬁc Literature Review
Members of the ISBER Biospecimen Science Working
Group performed a critical review of these literature sources
to ﬁnd published data demonstrating that speciﬁc
biomarkers are particularly unstable and sensitive to pre-
analytical variations, or to ﬁnd assays that can be used to
assess such variations. The objective of the working group
to identify unstable analytes was thus directly opposite to
the typical focus of studies conducted to identify the
analytical stability of speciﬁc analytes or high-throughput
signatures.
References were classiﬁed and reviewed in ﬁve thematic
categories: i) single analytes; ii) hormones, cytokines, and
nutritional indicators; iii) high-throughput methods;
iv) functional assays; and v) pathogens.
Publications on single analytes (primarily in blood or
urine) were expected to contain information on the most
immediately useful diagnostic markers. We attempted to
identify markers that had an on/off response to speciﬁc
preanalytical variations, such as those in which enzymatic or
immunological activity is completely lost. This condition
makes it clear that the change is signiﬁcant, and that abso-
lute reference values are not needed. A considerable degree
of degradation (eg, a 60% drop in 30 minutes at room
temperature) was also considered to be very important,
because we can assume that the presence of the corre-
sponding marker or activity will completely disappear under
more stressful conditions (eg, 2 hours at room temperature).
In publications on hormones, cytokines, and nutritional
indicators in blood, reference values were expected to be
found, at least for clinically important analytes.
High-throughput methods (-omics) include arrays (DNA,
RNA) and mass spectrometry. No absolute reference values
were expected to be found, but publications addressingThe Journal of Molecular Diagnostics - jmd.amjpathol.orgthese methods were expected to provide information on the
most immediately useful predictive markers.
For publications on functional assays (eg, in blood cells),
no absolute reference values were expected to be found.
Data from publications on pathogens could support
development of spiking-based QC tools.
A set of data items was extracted and recorded from each
relevant publication in a common matrix, as follows:
reference; type or types of samples studied; preanalytical
variable or variables studied; range of preanalytical variable
studied (range of variation applied); preanalytical threshold
identiﬁed; potential QC tool or marker (sample character-
istic assessed); QC method [eg, enzyme-linked immuno-
sorbent assay (ELISA), RT-PCR]; type of method
(qualitative or quantitative, simple or multiplex); range of
the potential QC tool/marker (range of measures observed as
a result of the preanalytical variation applied); control
samples used as baseline; and, in the case of quantitative
methods, the reference ranges (expected values of the
potential QC marker in a general population). Based on
these elements, the most appropriate QC tools, in terms of
molecular diagnostic performance and feasibility of appli-
cation, were selected by consensus.
In all, 494 references on human biospecimen science
were collected between 2008 and 2010 and reviewed in
2011; of these, 287 were studies performed in a clinical
setting, 185 were studies performed in a research setting
(Figure 2), and 22 were publications from the Cooperative
Human Tissue Network. The full compilation is available at
http://www.isber.org/wg/bs/documents/isberbswgliterature
compilation.pdf (3rd edition, September 2011; last accessed
May 2012). The 494 publications came from 225 different
journals. The most frequently cited journals were Clinical
Chemistry (67 publications), Clinical Chemistry and Labo-
ratory Medicine (28 publications), and Cancer Epidemi-
ology, Biomarkers & Prevention (17 publications). All of
the remaining journals had fewer than 10 publications.
Classiﬁcation of Potential QC Tools
Based on the data from the literature review, we evaluated
some of the marker tools using four criteria: type of QC tool,
evidence base, applicability grade, and accessibility grade.
Type of QC Tool
The QC tools can be categorized into two main types:
diagnostic and predictive.
1. Diagnostic tools assess the processing steps of the bio-
specimen, such as delay of processing, time or type of
ﬁxation, or storage duration.
2. Predictive tools assess the feasibility and/or reliability of
the downstream analysis. This is particularly important
for high-throughput methods, as predictive of successful
method performance.5
Figure 2 Biospecimen science literature compilation of human biospecimen science studies in a clinical (A) or a research (B) setting. Asterisks mark
groups of publications reviewed for this study.
Betsou et alEvidence Based
QC tools from recommendations that were not evidence-
based were not retained for further review.
Applicability Grade
Applicability was assessed in three grades: immediate,
potential, and no applicability.
1. For a grade of immediate applicability, a threshold is
identiﬁed for the preanalytical variation (eg, a maximum
delay of processing) and the absolute value of a reference
(control population) range is known. Only a few articles
met these criteria.62. For a grade of potential applicability, a threshold is
identiﬁed but the absolute value of a reference range is
not known. In other cases of potential applicability,
accelerated aging studies are performed but real-time
stability testing is not performed, or native concentra-
tions of analytes are too low for immediate application
but a spiking approach with a recombinant antigen or
a synthetic molecule may be possible.
3. For a grade of not immediately applicable, more stressful
conditions would need to be applied to the biospecimen
to assess a suitable threshold.
QC tools graded as of immediate applicability require
further validation studies. QC tools in the other two grades
require feasibility or proof-of-principle studies.jmd.amjpathol.org - The Journal of Molecular Diagnostics
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Another key element for assessing the usefulness of a QC
tool is how user-friendly and accessible the corresponding
method may be: readily, potentially, or not immediately
accessible.
1. The readily accessible grade includes classical laboratory
methods (eg, ELISA, PCR, ﬂow cytometry).
2. The potentially accessible grade includes methods re-
quiring high-throughput platforms (eg, microarray plat-
form, mass spectrometry platform) that are typically
available as a centralized service.
3. The not immediately accessible grade includes laboratory-
developed (in-house) methods.Identiﬁcation of Potential QC Tools
Potential QC tools were identiﬁed in the above-mentioned
ﬁve thematic categories.
The single analyte group of publications consisted
primarily of targeted stability studies. The speciﬁc analytes
were measured by methods usually applied in clinical
biology.
The hormones, cytokines, and nutritional indicators group
of publications consisted of stability studies of these speciﬁc
molecules.
The high-throughput group of publications, gene
expression microarray or mass spectrometry data were
compared for samples that had undergone stressful condi-
tions versus their baseline conditions.
In the functional assays group of publications, a variety
of cytology specimen types were studied (including FFPE,
cervical cytology, bone marrow, saliva, buccal specimens,
blood, and urine), with checking for changes in DNA
under different collection or storage conditions as the
overall goal. Most of these publications used DNA yield as
the endpoint for QC; in some of the studies, researchers
looked for DNA ampliﬁcation by PCR, and in others at the
level of whole-genome analysis, single-nucleotide poly-
morphism analysis, or single-strand breaks. Also, blood
cells (peripheral blood mononuclear cells, natural killer
cells, and T cells) and sperm were checked for cell
viability and cell biological functions using standard QC
tests for IFN-g, CD4þ, natural killer cell activity, CD8þ,
HIV infectivity, and cytokine production (IL-2, IL-6, IFN-g,
TNF-a, GM-CSF). Different types of cells (eg, cell lines,
tissue, sperm, cornea, and stem cells) were tested for cell
viability and DNA integrity that had undergone various
processing and storage conditions. Mass spectrometry
studies were performed on semen and urine, and QC was
determined by the number of chromatographic peaks
generated.
The pathogens group of publications consisted primarily
of stability studies of viral pathogen nucleic acids in serum
or plasma.The Journal of Molecular Diagnostics - jmd.amjpathol.orgDiagnostic QC Tools
The most readily applicable and accessible evidence-based
QC tools are summarized in Table 1.
For Serum and Plasma Specimens
Transferrin receptor. De Jongh et al7 showed a 90% increase
of soluble transferrin receptor, measured by ELISA in
serum, after an 8-hour blood precentrifugation delay; they
reported a reference range of 171 to 212 U/mL.
Ascorbic acid. Karlsen et al8 suggested ascorbic acid,
measured by chromatography, as a potential QC tool in
serum and plasma. Ascorbic acid showed a 70% decrease
in serum or EDTA plasma, after a 6-hour blood
precentrifugation delay at room temperature, as well as
a 100% decrease in serum and EDTA plasma after 3
months of storage at 20C. The authors did not report
a reference range, but this is known from the clinical
chemistry to be 26 to 85 mmol/L.30
Potassium. Heins et al9 showed that blood precentrifugation
delay at 4C induced a dramatic increase in potassium
concentration about 200% after 1 day and up to 500% after
7 days of processing delay. The increase was less
pronounced after delay at room temperature, because of the
temperature-dependent activity of the Naþ-Kþ-ATPase.
The mean baseline value has been reported as 3.92 mmol/L,
measured by indirect potentiometry,9 and the standard
reference range is 3.29 to 4.50 mmol/L.31
GM-CSF, IL-1a, and G-CSF. Ayache et al10 performed ELISA
to examine the global chemokine and cytokine proﬁle in
EDTA plasma collected with or without protease inhibitors.
A 2-hour precentrifugation delay at room temperature
induced an 11- to 20-fold increase of GM-CSF, IL-1a, and
G-CSF in blood collected without protease inhibitors and
a 7- to 10-fold increase of the same proteins in blood
collected with protease inhibitors. Baseline reference levels
were reported as 214  163 pg/mL for GM-CSF, 9.4  7.7
pg/mL for IL-1a, and 119  60 pg/mL for G-CSF.
C3a chain and ﬁbrinogen peptides. Using matrix-assisted
laser desorption/ionization-time of ﬂight (MALDI-TOF)
mass spectrometry, Marshall et al11 showed for the ﬁrst
time a characteristic family of complement C3a chain
and ﬁbrinogen peptides generated in citrated plasma and
exposed to room temperature for 4 hours. These ﬁndings
have been conﬁrmed by Yi et al32 in serum and in EDTA,
citrated, and heparinated plasma and by West-Nørager
et al33 for a 2-hour postcentrifugation delay of serum at
either room temperature or 4C using MALDI-TOF mass
spectrometry. The following peptides were identiﬁed as
involved in postsampling modiﬁcations in serum:
complement C3f, aa 2-16 (SKITHRIHWESASLL);
complement C3f, aa 1-16 (SSKITHRIHWESASLL);7
Table 1 Biospecimen Molecular Diagnostic Tools Identiﬁed, with QC Scope and Evaluation
QC tool References
Analyte
type Sample type QC scope
Applicability
grade
Accessibility
grade
Future research
required
Transferrin receptor 7 Protein Serum Precentrifugation
delay
1 1
Ascorbic acid 8 Vitamin Serum, EDTA
plasma
Precentrifugation
delay, storage
conditions
1 2 Longer
precentrifugation
delay to get 100%
degradation
Kþ 9 Ion Serum Precentrifugation
delay at 4C
1 1 Plasma
GM-CSF, IL-1a, G-CSF 10 Protein EDTA plasma
 PI
Precentrifugation
delay
1 1
C3f peptides, ﬁbrinopeptide A 11 Peptide Serum,
plasma
Postcentrifugation
delay
3 2
ACTH 12 Hormone EDTA plasma,
serum
Postcentrifugation
delay
3 1 Longer delays to
assess the
threshold of ACTH
complete
degradation in
both serum and
plasma
sCD40L 13 Protein Serum Exposure to room
temperature
1 1
Vitamin E 14 Vitamin EDTA plasma Storage conditions 1 1
MMP-9 15 Protein Citrated
plasma
Storage conditions 2 1 healthy donors,
Degradation in
EDTA plasma and
serum
VEGF 16 Protein Serum Freeze thawing,
storage conditions
2 1 Real-time stability
testing
IL-1b, IL-10, IL-15 17 Protein Heparin
plasma
Storage conditions 2 1 Stability in other
anticoagulants
and in serum
MMP-7 18 Protein Serum Freeze thawing 1 1 Stability in
plasma and saliva
IL-15, IL-17, IFN-g 17 Protein Heparin
plasma
Freeze thawing 2 1 Stability in other
anticoagulants
and in serum
ICAM1, SLC7A5 24 RNA EDTA PBMCs Precentrifugation
delay at room
temperature
2 1 More subjects,
other
anticoagulants,
define reference
intervals
AdenosineA2a receptor, T cell
receptor a locus, T54
protein, tumor necrosis
factor superfamily member
14 putative lymphocyte
G0/G1 switch gene,
inhibitor of DNA binding 1
dominant negative helix-
loop-helix protein,
diphtheria toxin receptor
19 RNA Citrate
PBMCs
Precentrifugation
delay at room
temperature
2 1 More subjects,
other
anticoagulants,
define reference
intervals
NR4A2, AREG///LOC653193,
MAFF
20 RNA ACD PBMCs Precentrifugation
delay at room
temperature
2 1 More subjects,
other
anticoagulants,
define reference
intervals
(table continues)
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Table 1 (continued )
QC tool References
Analyte
type Sample type QC scope
Applicability
grade
Accessibility
grade
Future research
required
TNF-a 21 Protein Urine Preprocessing delay 2 1 Spiking approach
Epinephrine, dopamine 22 Compound Urine Storage conditions 1 2 Effect of freeze
thawing
a-1-Antitrypsin 23 Protein Urine Freeze thawing 3 1 Longer
preprocessing
delays in order to
define a threshold
for 100%
degradation and
more freeze thaw
cycles.
Truncated cystatin-C 24 Protein CSF Storage conditions 3 3 Produce mAbs
once
confirmation in
other sample
types
T-cell IFN-g response 25 Protein Viable PBMCs Storage conditions 3 1 More prolonged
cryopreservation
DUSP1 expression 26 RNA Fresh
prostatic
tissue
Warm ischemia
time
1 1 Other tissue types
Dusp1, 1a, Egr1, bHLHe40
(alias bHLHb2), Ppp1r15a
(alias Gadd34; alias
Myd116), Slc25a25, Btg2,
Cxcl1, Zfp36, Jun
27 RNA Frozen tissue Cold ischemia time 2 1 Different types of
human tissues
and reference
ranges
p-Tyrosine, ERBB2 (alias
HER2; alias Neu)-Tyr1248,
FAK
28 Protein Breast tissue Cold ischemia time 1 1 Other tissue types
Myosin heavy chain, smooth
muscle isoform
38 Protein Prostatic
tissue
Cold ischemia 3 2 Other tissue
types, reference
values
ACD, acid-citrate-dextrose; ACTH, adrenocorticotropic hormone; CSF, cerebrospinal ﬂuid; mAbs, monoclonal antibodies; PBMC, peripheral blood mono-
nuclear cell; PI, protease inhibitors.
Evidence-Based Biospecimen QC Toolscomplement C3f, aa 1-17 (SSKITHRIHWESASLLR);
ﬁbrin a C term fragment, aa 81-105 (SSSYSKQFTSSTS-
YNRGDSTFESKS); ﬁbrin a C term fragment, aa 81-106
(SSSYSKQFTSSTSYNRGDSTFESKSY); ﬁbrinopeptide
A, aa 1-12 (EGDFLAEGGGVR); ﬁbrinopeptide A, aa 3-16
(SGEGDFLAEGGGVR); ﬁbrinopeptide A, aa 2-16 (DSG-
EGDFLAEGGGVR); ﬁbrinopeptide A (modiﬁcations: Ser-3
phosphorylated), aa 1-16 (ADSGEGDFLAEGGGVR);
kininogen, aa 439-456 (HNLGHGHKHERDQGHGHQ).
ACTH and BNP. Evans et al12 studied the stability of plasma
and serum hormones and conﬁrmed the instability of
adrenocorticotrophic hormone (ACTH) and brain natriuretic
peptide (BNP). Reference ranges are 10 to 64 pmol/L
(measured by immunoradiometric assay) for ACTH and 34
to 153 pmol/L (measured by radioimmunoassay) for BNP.
However, BNP levels in healthy donors are at or near the
detection limit of the assay; this quality marker can beThe Journal of Molecular Diagnostics - jmd.amjpathol.orguseful only in heart failure subjects and is therefore not of
general use. A clinically signiﬁcant decrease in ACTH
levels was observed after storage at room temperature for 8
hours in EDTA plasma and after only 1 hour in serum.
CD40L. Lengelle et al13 reported soluble CD40L (sCD40L)
as a QC marker that allows assessment of serum exposure
to elevated temperatures. They found that that sCD40L,
measured by ELISA, undergoes complete degradation in
12 hours at 37C or in 48 hours at room temperature.
Also, freeze-thaw cycles had no effect on sCD40L levels
in serum. They reported a reference range of 7 to 17 ng/mL,
and the precise threshold below which signiﬁcant
exposure to elevated temperatures can be ascertained as
4.3 ng/mL.
Vitamin E. Ocke et al14 reported that vitamin E in EDTA
plasma decreased by more than 90% when plasma was9
Betsou et alstored for more than 24 months at 20C. The analytical
method used was high performance liquid chromatography.
They reported the reference range as 19 to 31 mmol/L.
MMP-9. Rouy et al15 showed complete degradation of
MMP-9 measured by ELISA in citrated plasma after 25
to 36 months of storage at 80C. Their reported
reference range for MMP-9, established in a population
of patients with acute myocardial infarction, was 80 to
800 ng/mL.
VEGF. Kisand et al16 recently showed that VEGF in serum is
labile to freeze-thawing and to storage duration either at
20C or at 80C. When VEGF was measured by
ELISA, it became undetectable after one to six freeze-
thaw cycles. Accelerated aging testing and Arrhenius plots
allow extrapolation to predict that VEGF becomes
undetectable after 11 months of storage at 20C or after
4.5 years of storage at 80C. The VEGF reference range
reported by enzyme immunoassay kit manufacturers (eg,
R&D Systems, Inc., package insert: Quantikine Human
Total MMP7 Immunoassay. Minneapolis, MN) is 62 to
707 pg/mL in serum. Although the results reported by
Kisand et al16 seem interesting, the lability of VEGF
exposed to freeze-thaw cycles has not been conﬁrmed,34
and application in plasma is not feasible, given that
reference levels in plasma may start from 0 pg/mL.
Interleukin cytokines. De Jager et al17 examined recovery
and stability of spiked cytokines in heparin plasma and
serum and showed that IL-1b, IL-10, and IL-15 were
completely degraded after 4 years of storage at 80C,
and IL-15, IL-17, and IFN-g were completely degraded
after four freeze-thaw cycles. However, for all of these
cytokines the reference ranges in healthy donors start from
0 pg/mL and are reported by ELISA kit manufacturers
to be lower than the lowest calibration point (eg, R&D
Systems, Inc., package insert: Quantikine Human IL-10
Immunoassay. Minneapolis, MN). Therefore, unless
ultra-sensitive detection methods are developed and used,
only a spiking strategy is possible for development of
corresponding QC tools.
MMP-7. Chaigneau et al18 showed complete loss of MMP-7
as measured by ELISA in serum after 30 freeze-thaw cycles.
The reference ranges reported by the kit manufacturer are
1.07 to 4.40 ng/mL in serum and 1.10 to 4.59 ng/mL and
3.80 to 28.3 ng/mL in plasma and saliva, respectively
(R&D Systems, Inc., package insert: Quantikine Human
Total MMP7 Immunoassay. Minneapolis, MN).
Adenosine A2a receptor and other genes. Using Affymetrix
microarrays, Baechler et al,19 found that a variety of signaling
pathways are activated in peripheral blood cells collected on
CPT cell preparation tubes and stabilized in RNAlater
reagent after ex vivo overnight incubation. Many of the10genes sensitive to ex vivo incubation are involved in
transcriptional regulation, cell cycle progression, and
apoptosis. Several of these genes also encode proteins that
perform functions essential to the immune response. Most
down-regulated (>40-fold) by the precentrifugation delay
were the adenosine A2a receptor, the T-cell receptor
a locus, the T54 protein, and the tumor necrosis factor
superfamily member 14 coding genes. Most up-regulated
(>70-fold) by the precentrifugation delay were the putative
lymphocyte G0/G1 switch gene, the inhibitor of DNA
binding 1 dominant negative helix-loop-helix protein, and
the diphtheria toxin receptor coding genes.
NR4A2, AREG///LOC653193, and MAFF genes. A similar study
performed by Barnes et al20 on peripheral blood mononuclear
cells collected in acid-citrate-dextrose tubes and stabilized in
TRIzol reagent, with a 4-hour delay, demonstrated that the
most sensitive genes (those with a greater than sevenfold
change after a 4-hour precentrifugation delay) were NR4A2,
AREG///LOC653193, and MAFF.
Epinephrine and dopamine. Boomsma et al22 showed
complete loss of epinephrine and dopamine measured by
high performance liquid chromatography and ﬂuorometry
in heparinized plasma after suboptimal storage conditions.
The suboptimal storage condition threshold identiﬁed was
2 to 3 days of storage at room temperature. Their reported
reference values were 0.24  0.10 nmol/L for epinephrine
and 0.11  0.03 nmol/L for dopamine.
For Urine Specimens
TNF-a. Banks et al21 described complete loss of TNF-a
measured by ELISA in urine after a preprocessing delay
of 30 minutes at 37C. However, given the low reference
values in urine (0.1  0.2 pg/mmol),35 only a spiking
approach would be feasible. [TNF-a concentration in
serum or plasma from healthy donors is <16 pg/mL,
which is the lowest calibration point of most ELISA
kits (R&D Systems, Inc., package insert: Quantikine
Human TNF-a Immunoassay. Minneapolis, MN).]
Epinephrine and dopamine. Boomsma et al22 showed
complete loss of epinephrine and dopamine measured by
high performance liquid chromatography and ﬂuorometry
in unpreserved urine after suboptimal storage conditions.
The suboptimal storage condition threshold identiﬁed was
10 days of storage at room temperature. Only the mean
baseline reference values were reported: 0.25 mmol/L for
epinephrine and 1.86 mmol/L for dopamine.
a1 Anti-trypsin. Tencer et al23 studied the stability of a1
anti-trypsin and found a signiﬁcant 35% decrease when
the urine prefreezing delay was either 7 days at room
temperature or 30 days at 4C, independent of the
presence of additives in the urine specimens. The a1 anti-
trypsin levels decreased by 35% after 1 day of storage atjmd.amjpathol.org - The Journal of Molecular Diagnostics
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temperature. The authors concluded that the degradation
was due to thawing, rather than to cryostorage. An
important interindividual variability was observed, with
reference ranges of 3 to 66 mg/L (median, 16 mg/L)
obtained by single radial immunodiffusion or automated
immunoturbidimetry.
For Cerebrospinal Fluid Specimens
Cystatin-C. Carrette et al24 reported that 3 months of storage
at 20C induced an N-terminal truncation of cystatin C, as
detected by MALDI-TOF mass spectrometry. Implementation
of such a QC assay would necessitate development of
monoclonal antibodies speciﬁc to the truncated N-terminal
end and to intact epitopes, thus allowing the performance of
ELISA and calculation of a ratio.
For Viable Blood Cell Specimens
IFN-g production. Owen et al25 studied the effect of
cryopreservation on apoptosis and T-cell responses to
different protein and peptide antigens. They showed that
long-term (1 year) cryopreservation increased apoptosis, as
measured by activated caspase 3 antibody staining, and
diminished CD4þ and CD8þ T-cell responses to both
cytomegalovirus lysate and to staphylococcal enterotoxin B
in HIV patients, with acute and chronic infection,
respectively, measured by IFN-g production. The mean
absolute decrease in the percentage of responding T cells
was only about 1%. Further research must be done to
determine whether more prolonged cryopreservation has
a more dramatic effect on these functional assays.
For Solid-Tissue Specimens
HPRT. Foss et al36 proposed RT-PCR of the hypoxanthine-
guanine phosphoribosyltransferase (HPRT) mRNA (168
bp) to assess the quality of parafﬁn-embedded tissue. Two
technical advantages of this method are that the primers
function with both human and mouse RNA (and so such
a QC tool can be applied to both types of specimens) and
that they preclude ampliﬁcation of genomic DNA.
However, although ampliﬁcation was effective on mouse
spleen tissues ﬁxed with Omniﬁx and Carnoy’s ﬁxative, it
was not effective on FFPE tissues.
DUSP1. Lin et al26 explored the effects of surgery-linked
warm ischemia on prostate tissue and showed that the
DUSP1 gene was signiﬁcantly up-regulated (14-fold
change) after surgery and ischemia. DUSP1 expression
was measured by both microarray and quantitative RT-
PCR. The CT value was shown to be <8. The reported
reference range in presurgical tissue was 7.5 < CT < 11.
Hspa1, Jun, and other genes. Thompson et al27 explored the
effect of cold ischemia at either room temperature or 37C and
the effect of thawing on RIN and global gene expression
proﬁles of rat liver tissue. They showed that cold ischemiaThe Journal of Molecular Diagnostics - jmd.amjpathol.orginduced signiﬁcant up-regulation of the rat genes Dusp1,
Hspa1a and Hspa1b, Egr1, bHLHe40 (alias bHLHb2),
Ppp1r15a (aliases Gadd34, Myd116), Slc25a25, Btg2,
Cxcl1, Zfp36, and Jun. The threshold in terms of number of
hours of incubation at 37C was not clearly indicated, and
reference ranges remain to be determined.
Fos. Almeida et al37 showed signiﬁcant up-regulation of the
Fos gene expression with cold ischemia in mouse liver.
Fos gene expression was increased by a factor of 12 after 3
hours at room temperature, as measured by quantitative
RT-PCR.
p-Tyr, ERBB2-Tyr1248, and PTK2. De Cecco28 studied the
effect of cold ischemia time on global gene expression
and on the phosphorylation status of molecular targets in
breast tissue. The phosphorylated epitopes p-Tyr, ERBB2-
Tyr1248, and PTK2 (alias FAK) were completely
denatured after 24 hours of cold ischemia and were
undetectable on tissue protein extract Western blot. Gene
expression signatures were also studied; but the identities
of the most sensitive genes were not reported.
Myosin heavy chain. Using two-dimensional differential gel
electrophoresis, Jackson et al38 compared the proteomic
proﬁles between prostatic tissue of different cold ischemia
times. Myosin heavy chain smooth muscle isoform
increased by six- to sevenfold after 5 hours of cold ischemia.
Predictive QC Tools
One of the main obstacles in performing high-throughput
DNA analysis on clinical samples is the limited starting
amounts of genomic DNA that can be obtained from these
samples. Whole-genome ampliﬁcation has allowed applying
high-throughput analysis in samples from which only
minute amounts of genomic DNA can be extracted. Such
samples include single cells,38 buccal swabs and blood
spots,39 ﬁne-needle aspirates, and tissue microdissection.40
The difﬁculty is even greater for FFPE tissues, in which
intra- and intermolecular cross-linking further limits the
access to and the quality of the biomolecules (Sigma-
Aldrich, Whole gene ampliﬁcation from archived formalin-
ﬁxed, parafﬁn-embedded tissues. St. Louis, MO). Whole-
genome ampliﬁcation has been key in generating larger
quantities of DNA, thereby permitting the application in
these samples of high-throughput genomic techniques,
including single-nucleotide polymorphism arrays39,40,41 and
methylation analysis (Illumina, Inc., Comprehensive DNA
methylation analysis on the Illumina Inﬁnium assay plat-
form. San Diego, CA).
Several ampliﬁcation approaches are available, including
multiple-displacement ampliﬁcation,39,41 OmniPlex tech-
nology,39,41,42 and restriction and circularization-aided
rolling circle ampliﬁcation (RCA-RCA).29 Of note, little
information is available on sample quality parameters that11
Betsou et alwould allow predicting the success of downstream whole-
genome ampliﬁcation in FFPE tissues.
Multiplex GAPDH PCR
Wang et al29 developed a simple approach to assessing
DNA fragmentation in very small clinical specimens of
widely different origins, including archival specimens. Their
approach predicts the likelihood of success of whole-
genome ampliﬁcation using RCA-RCA and subsequent
PCR. The method is based on a multiplex PCR using four
GAPDH amplicons of varying sizes. Even if minimal
quantities of longer PCR fragments (approximately 300 to
400 bp) are visible, the subsequent RCA-RCA and PCR-
based assays are still successful. Only colon and glioblas-
toma were studied (after 5 to 7 years or 10 to 12 years of
ﬁxation, respectively); other tissues and formalin ﬁxation
times remain to be explored. More importantly, this tool was
used to evaluate the effect of formalin ﬁxation time on the
quality of DNA.
RT-PCR Efﬁciency
Player et al43 analyzed a panel of RNA quality parameters to
predict successful hybridization on a microarray chip.
Parameters considered included general ranges of absor-
bance, rRNA ratios, and RIN (before the array). More
importantly, according to the authors’ protocol, 1000-fold
ampliﬁcation should happen in the ﬁrst round of RT-PCR.
Less than expected ampliﬁcation is indicative of poor
RNA quality and should preclude proceeding with the
microarray experiment. It would be important to consis-
tently apply these criteria to RNA from tissues (frozen or
even FFPE tissues), and not only to RNA from cultured
cells.
28S RNA Quantitative RT-PCR
Roberts et al44 identiﬁed simple QC quantitative RT-PCR
assays as tools to predict success in subsequent microarray
analysis of formalin ﬁxed specimens. A DDCT value of <15
for the 28S RNA between archival tissue and the universal
RNA predicts array results of good quality (40% calls in 21/
24 samples). In addition, if the absolute value of the 28S
RNA CT is <15, the quality of the array data is similar to
that of data from frozen specimens. The authors reported
other data regarding conventional RNA quality parameters,
including the ﬁnding that RIN > 4 correlates with >35%
calls. It would be useful to expand the tissue types analyzed
(lung and colon were the main tissues studied), as well as to
analyze minute dissected specimens (only whole tissue
sections were studied).
Phosphoproteins
Espina et al45 studied phosphoprotein proﬁles in tissues
subjected to different lengths of time at room temperature to
assess phosphoprotein stability. They measured 53 signal
pathway phosphoproteins over time. Phosphoprotein stability
is signiﬁcantly affected by time at room temperature in12tissues. Both up- and down-regulation of several phos-
phoproteins were observed as early as within 30 minutes
after excision. This information is important for assess-
ment of the overall phosphoprotein stability of solid-tissue
specimens.
RNA Integrity Number
Thompson et al27 showed the predictive value of RIN on the
gene expression microarray performance. RIN  7 was
associated with signiﬁcant decreases of the microarray
sensitivity and speciﬁcity. It will be important to assess this
data on both frozen and ﬁxed human specimens.Discussion
Several studies have addressed the effects of preanalytical
variables on the molecular quality of biospecimens. Such
concerns have been reﬂected in continued discussions at
scientiﬁc meetings (eg, the annual ISBER and BRN
symposia), as well as further work by ISBER and by the
National Cancer Institute in developing evidence-based best
practices for biospecimen collection, storage, and process-
ing. However, as the present literature review indicates,
additional research is still required to clearly elucidate the
effects of preanalytical variables on biospecimens, along
with the effects on downstream research activity.
There is still a lack of consensus regarding which markers
or tools are the most useful for assessing sample quality.
As the effects of biospecimen processing on the quality of
research data become better recognized and better under-
stood, we can hope that a more general effort in identifying
useful quality-assurance and quality-control (QA/QC)
markers and tools will be appreciated by the biospecimen
science community.
This review does not address current widely used QC
assays, such as nucleic acid spectrophotometry, RIN, or
PCR, nor historical QC tools (eg, brain tissue pH, assumed
to result from hypoxia46), such as have recently been
reviewed in the third edition of the ISBER Best Practices5 or
suggested in the literature in the form of recommendations.47
Instead, here we review indices for novel and evidence-based
QC assays with reasonable biospecimen molecular diagnostic
potential.
Most of the publications reviewed were observational
studies, in that they observed biospecimen behavior relative
to differences in processing or characterization methods. We
believe that fundamental biospecimen research is also
needed to explain the underlying mechanisms (eg, protease
enzymatic activities underlying protein concentration
changes, activation of cellular pathways underlying gene
expression changes, oxidation and single-strand breaks
underlying DNA degradation, or methylation-chromatin
conformation underlying stem cell pluripotency status).
This kind of research could lead to better solutions for
stabilizing biospecimens.jmd.amjpathol.org - The Journal of Molecular Diagnostics
Evidence-Based Biospecimen QC ToolsThe main goal of the present literature review was to
identify markers and assays for the evaluation of quality of
specimens. However, another approach in biospecimen
science is to increase the range of molecular techniques that
can be applied to specimens, circumventing their inherent
challenges, particularly those presented by archival FFPE
tissues. For example, antigen retrieval for FFPE material has
not only improved immunohistochemical and proteomics
analysis of tissues48e51), but has also led to further
development of DNA and RNA extraction from FFPE tissues,
shedding light on this difﬁcult topic of biospecimen QC.48,52
Although some ﬁndings have been conﬁrmed by multiple
research teams, it appears that the most reliable QC tools
will have to be deﬁned and validated for each type of bio-
specimen. For example, multiple teams have conﬁrmed the
instability of Fos and Junb gene expression with cold
ischemia in tissues,38,53,54 as well as the instability of
ascorbic acid with blood precentrifugation delay and serum
storage conditions8,55 and of the serum complement C3 and
ﬁbrinopeptides with postcentrifugation delays.11,32,33
It is unlikely that a single marker can provide all of the
information required regarding sample quality. For example,
the most frequently used characterization tool, nucleic acid
quantiﬁcation, is not enough. The question arises as to what
might be the lower threshold of total RNA input needed to
obtain consistent high-throughput data, such as RNA arrays.
Ten nanograms might be enough if pristine RNA is used
from cell lines, but not necessarily if from tissue RNA, in
which case the biomolecule integrity might be compro-
mised.56 Furthermore, a single universal QC assay cannot
cover all aspects of biospecimen characterization. The use
of the suggested QC tools is not to certify a biospecimen as
being of high or low quality, but rather to diagnose speciﬁc
preanalytical conditions (eg, a serum sample having
undergone more than 24 hours at room temperature condi-
tions). Obviously, the signiﬁcance of such conditions
differs, depending on the speciﬁc downstream analyte, with
different analytes having different robustness to the same
conditions. Therefore, a panel of carefully selected QCFigure 3 Models of QC tools. Baseline reference ranges are indicated as mean va
(green diamonds) reference values. The (shaded area) red squares corresponds to an a
upstream processing of the sample can be drawn. A: Linear degradation of the QC ma
The Journal of Molecular Diagnostics - jmd.amjpathol.orgmarkers will be needed to comprehensively assess bio-
specimen quality, and speciﬁc knowledge will be required
on the inﬂuence of speciﬁc collection and/or processing
conditions on each downstream assay.
Another challenge is the lack of population reference
ranges for the majority of research biomarkers. The
usefulness of a surrogate quality biomarker can be assessed
only if we know the corresponding population reference
ranges. We present a model of surrogate QC markers with
either linear or exponential degradation rate on speciﬁc
preanalytical conditions (Figure 3). Knowledge of the
baseline reference ranges in the population of interest is
necessary to be able to deﬁne the lower threshold value of
the analyte, below which we can be certain that the bio-
specimen underwent conditions more stressful than those of
the corresponding intercept. With linear degradation
(Figure 3A), biospecimens that show <60 arbitrary units
(AU) of analyte (minus the analytical uncertainty of the
method) have undergone >5 preanalytical factor stress
units. Similarly, with exponential degradation (Figure 3B),
biospecimens that show <60 AU of analyte (minus the
analytical uncertainty of the method) have undergone >2
preanalytical factor stress units. Diagnostic performance
depends on the degradation kinetics. It is obvious, with the
degradation kinetics shown in Figure 3, that a biospecimen
molecular diagnostic tool with linear degradation will be
more speciﬁc, whereas one with exponential degradation
will be more sensitive.
To deﬁne QC thresholds, one must know the reference
ranges in both healthy and diseased subjects4 and also take
into account the analytical imprecision. Only then can
a marker cutoff be deﬁned, beyond which it is certain that
a biospecimen has undergone a minimum amount of a speciﬁc
preanalytical stress independent of the initial level of the
marker used. For high-throughput studies in which thousands
of data points are generated on a single sample, a traditional
absolute value for the reference is not available.
Development of novel QC tools through spiking
approaches can overcome difﬁculties linked to very lowlues in the population (blue diamonds) and as upper (red diamonds) and lower
rbitrary threshold of the QC marker below which diagnostic conclusions as to the
rker. B: Exponential degradation of the QC marker. AU, arbitrary units.
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contents of the primary collection tubes can be spiked with
a recombinant antigen or synthetic molecule, if it has been
demonstrated that this molecule undergoes degradation
once in the native biospecimen environment. The spiking
approach could be applicable to QC tool development based
on observations of pathogen nucleic acid instability in bio-
specimens, such as instability of hepatitis C viral RNA in
serum.57 The spiking approach would require that a critical
amount of the spiking molecule is included up front in the
collection tubes by the manufacturers. However, such an
approach would prevent downstream applications targeting
these pathogen spiking molecules.
For high-throughput studies, few reports identiﬁed
markers with predictive value for downstream analysis.
Most studies assessed the quality of the results after the
downstream assay had been performed; for example, quality
parameters such as noise, background, 30:50 ratio, or
percentage present calls might be assessed for a 54,000-gene
array. However, a method to predict the success of the
downstream analysis is important, not only because high-
throughput approaches are usually expensive, but also
because precious clinical specimens might be the limiting
factor, especially for research.
For predictive markers, our literature review revealed
that, although authors may recommend some particular
number or threshold, such as using RNA with certain
parameters, this recommendation is usually not based on
proven evidence.
In some cases, animal models can allow identiﬁcation of
QC tools applicable to human biospecimens. For example,
postmortem salmon RNA stability has been shown to be
tissue-type dependent,58 and mouse phosphorylated
protein status has been shown to be greatly inﬂuenced by
the postmortem interval.59 A QC marker identiﬁed in an
animal model may be applied to human biospecimens if
the corresponding molecule or pathway is expressed in
both.
We derived potential QC tools from publications that
were not intended to identify quality-assurance and quality-
control (QA/QC) markers. Most studies had a different aim,
such as the development of a technique. In most of these
cases, the data need to be validated on a larger scale. Only
through large-scale international validation exercises will
we be able to reach a consensus on the most reliable QC
markers, introduce them into proﬁciency testing programs60
and into biobank accreditation schemes, and establish
reference ranges, and so ultimately incorporate them into
future reporting recommendations.61
To standardize the assays to be used to assess the
molecular integrity of biospecimens, candidate QC tools
such as those identiﬁed in the present review should be
validated by large biospecimen research project consortia.
They should also be cross-checked against previously
established upstream QC tools, such as the RIN (method
comparison), and against downstream QC metrics, such as14microarray metrics (method performance). Critical windows
of preanalytical variations and biospecimen quality ranges,
such as would be acceptable for speciﬁc applications, could
ultimately be identiﬁed by large biospecimen research
consortia studying different applications, including high-
throughput sequencing, multiplex PCR, epigenetics, gene
expression, microRNA, and protein arrays.References
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